Diabetic Monitoring Analyzers Are Small, Convenient, and Cost-Effective

Two analyzers were introduced to meet the growing global demand for improved management of diabetes.

Offering improved outcomes and reducing the healthcare burden, Quo-Test and Quo-Lab were developed to provide simplicity and performance at a low cost per test.

A single drop of blood from a finger prick sample is needed to provide HbA1c results in four minutes using the new analyzers. HbA1C is a specific type of glycated hemoglobin, formed when glucose present in the blood attaches to hemoglobin. Whereas a blood glucose test can only measure what the blood glucose level is at the moment the test is done, an HbA1c test provides a way of assessing the average blood glucose level over the previous 6-8 weeks.

Globally recognized as the gold standard indicator of metabolic control of blood glucose, regular HbA1c monitoring helps minimize the long-term complications of diabetes, improve health outcomes, and reduce the escalating financial burden of the disease.

With full data connectivity and print options the newly introduced instruments deliver precise, accurate results wherever they are needed, in the laboratory or at the point of care (POC).

Quotient Diagnostics (Walton on Thames, UK) introduced the diabetic monitoring analyzers for the first time in the United Arab Emirates (a region where the disease is a major health issue) in January 2010 at the Arab Health exhibition in Dubai (UAE).

Diabetes is a major health issue in The United Arab Emirates, which has the second highest diabetes rate in the world. The disease is at the top of the agenda for the region's health professionals.

Related Links:
Quotient Diagnostics
Arab Health exhibition in Dubai